Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 25.74
- Piotroski Score 3.00
- Grade Buy
- Symbol (TYRA)
- Company Tyra Biosciences, Inc.
- Price $15.33
- Changes Percentage (-3.4%)
- Change -$0.54
- Day Low $15.33
- Day High $16.09
- Year High $29.60
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/18/2025
- Fiscal Year End N/A
- Average Stock Price Target $32.00
- High Stock Price Target $33.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.69
- Trailing P/E Ratio -11.7
- Forward P/E Ratio -11.7
- P/E Growth -11.7
- Net Income $-69,134,000
Income Statement
Quarterly
Annual
Latest News of TYRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Brutal hours, tyrants and chest pains: a freelance producer on the reality of British TV
Freelancers in the TV industry are overworked and undervalued, facing long hours, lack of breaks, and constant pressure to deliver with little support or appreciation. Despite being the backbone of th...
By The Guardian | 1 week ago -
In Light Of The Recent Hurricane Helene Disaster & Government's Impotent & Tyrannical Response, Is It Time To Bring Back Civil Defense?
The article discusses the idea of reviving Civil Defense in light of recent disasters like Hurricane Helene. It questions the government's response and suggests that trained civilians could be more ef...
By The Washington Standard | 2 weeks ago -
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
Tyra Biosciences' CFO, Alan Fuhrman, bought $152k worth of TYRA stock at $16 per share, increasing his holdings by 284%. This insider purchase signals optimism. With 4....
By Yahoo! Finance | 2 weeks ago
